dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

Drug Information

Indication: GI symptoms of functional, non-ulcer dyspepsia (chronic gastritis) ie, sensation of bloating, early satiety, u...

Indication: Peptic ulcer disease associated w/ Helicobacter pylori.

Indication: Symptomatic relief of nausea & vomiting of functional, organic, infectious or dietary origin, induced by r...

Indication: Healing & maintenance of erosive or ulcerative GERD. Healing of duodenal ulcers. Pathological hypersecreto...

Dosage: Dissolution of cholesterol gallstones; stones must be radioluscent & gallbladder must be functioning; chol

Actal
alexitol sodium

Indication: Relief of stomach discomfort eg, indigestion, heartburn due to gastric hyperacidity & peptic ulcer.

Alka-Seltzer
aspirin + citric acid + sodium bicarbonate

Indication: Relief of headache & upset stomach. Fever, colds & flu discomfort, muscular aches & pains.

Indication: Active duodenal, benign gastric, stomal & recurrent ulceration, persistent dyspeptic symptoms w/ or w/o ul...

Axcel Eviline
activated polymethylsiloxane + aluminium hydroxide...

Indication: Peptic ulcer, dyspepsia of functional or organic origin, heartburn in hiatus hernia or pregnancy, flatulence &...

Baroscon Double Action
calcium carbonate + sodium alginate + sodium bicar...

Indication: Symptomatic treatment of GERD eg, acid regurgitation, heartburn & indigestion; hyperacidity symptoms.

1  /  12
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 14 Aug 2018
A new study reinforces the gut-brain connection in Alzheimer’s disease (AD), untangling the complex interplay between gut and brain health that could potentially lead to new therapies targeted at manipulating the gut microbiome to treat AD.
Roshini Claire Anthony, 12 Jul 2019

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.